To provide a novel comparative analysis of cisplatin responses across different PDAC cell lines, in this study we used four pancreatic cancer cell lines [BxPC-3, Mia Paca-2, PANC-1, YAPC] with several different genotypic and phenotypic characteristics to examine and evaluate any differences in their response to cisplatin, focusing on the activation of the ERK1/2 pathway and its potential role in enhancing drug resistance. The gene discussed is MAPK3; the disease is familial pancreatic carcinoma.